IC43 + Placebo

Phase 2Completed
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumonia, Ventilator-Associated

Conditions

Pneumonia, Ventilator-Associated

Trial Timeline

Dec 1, 2008 → Feb 1, 2010

About IC43 + Placebo

IC43 + Placebo is a phase 2 stage product being developed by Valneva SE for Pneumonia, Ventilator-Associated. The current trial status is completed. This product is registered under clinical trial identifier NCT00876252. Target conditions include Pneumonia, Ventilator-Associated.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT01563263Phase 2/3Completed
NCT00876252Phase 2Completed
NCT00778388Phase 1Completed

Competing Products

20 competing products in Pneumonia, Ventilator-Associated

See all competitors
ProductCompanyStageHype Score
CAL02 Low-dose + CAL02 High-dose + PlaceboCombioxinPhase 1
25
tacrolimusAstellas PharmaPre-clinical
23
Cefiderocol + Best Available TherapyShionogiPhase 3
77
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
77
Cefiderocol + Standard of Care AntibioticShionogiPhase 1
33
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
52
doripenemJohnson & JohnsonApproved
85
levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 2/3
65
LevofloxacinJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
77
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + DoripenemJohnson & JohnsonPhase 2
52
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
52
Ceftazidime-avibactamAbbViePhase 1
33
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Tedizolid phosphate + LinezolidMerckPhase 3
77
Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
77